tetano
Editor, Senior Moderator
Am Heart J. 2020 May 13. doi: 10.1016/j.ahj.2020.05.002. [Epub ahead of print]
Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Lopes RD[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3,[/SUP][SUP]4[/SUP], Macedo AVS[SUP]1,[/SUP][SUP]4,[/SUP][SUP]5[/SUP], de Barros E Silva PGM[SUP]3[/SUP], Moll-Bernardes RJ[SUP]1[/SUP], Feldman A[SUP]1,[/SUP][SUP]4[/SUP], D'Andr?a Saba Arruda G[SUP]1,[/SUP][SUP]4[/SUP], de Souza AS[SUP]1,[/SUP][SUP]6,[/SUP][SUP]7[/SUP], de Albuquerque DC[SUP]1,[/SUP][SUP]8[/SUP], Mazza L[SUP]3[/SUP], Santos MF[SUP]1[/SUP], Salvador NZ[SUP]1[/SUP], Gibson CM[SUP]9[/SUP], Granger CB[SUP]2[/SUP], Alexander JH[SUP]2[/SUP], de Souza OF[SUP]1,[/SUP][SUP]4[/SUP].
Author information
Abstract
Background:
Angiotensin-converting enzyme-2 (ACE2) may increase due to upregulation in patients using angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB). Because renin-angiotensin system blockers increase levels of ACE2, a protein that facilitates coronavirus entry into cells, there is concern that these drugs could increase the risk of developing a severe and fatal form of COVID-19. The impact of discontinuing ACEI and ARBs in patients with COVID-19 remains uncertain.DESIGNBRACE CORONA is a pragmatic, multicenter, randomized, phase IV, clinical trial that aims to enroll around 500 participants at 32 sites in Brazil. Participants will be identified from an ongoing national registry of suspected and confirmed cases of COVID-19. Eligible patients using renin-angiotensin system blockers (ACEI/ARBs) with a confirmed diagnosis of COVID-19 will be randomized to a strategy of continued ACEI/ARB treatment versus temporary discontinuation for 30 days. The primary outcome is the median days alive and out of the hospital at 30 days. Secondary outcomes include progression of COVID-19 disease, all-cause mortality, death from vascular causes, myocardial infarction, stroke, transient ischemic attack, new or worsening heart failure, myocarditis, pericarditis, arrhythmias, thromboembolic events, hypertensive crisis, respiratory failure, hemodynamic decompensation, sepsis, renal failure, troponin, B-type natriuretic peptide, N-terminal-pro hormone and D-dimer levels.
Summary:
BRACE CORONA will evaluate whether the strategy of continued ACEI/ARB therapy compared with temporary discontinuation of these drugs impacts clinical outcomes among patients with COVID-19.
? 2020 Elsevier Inc. All rights reserved.
PMID:32405071PMCID:PMC7219415DOI:10.1016/j.ahj.2020.05.002
Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Lopes RD[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3,[/SUP][SUP]4[/SUP], Macedo AVS[SUP]1,[/SUP][SUP]4,[/SUP][SUP]5[/SUP], de Barros E Silva PGM[SUP]3[/SUP], Moll-Bernardes RJ[SUP]1[/SUP], Feldman A[SUP]1,[/SUP][SUP]4[/SUP], D'Andr?a Saba Arruda G[SUP]1,[/SUP][SUP]4[/SUP], de Souza AS[SUP]1,[/SUP][SUP]6,[/SUP][SUP]7[/SUP], de Albuquerque DC[SUP]1,[/SUP][SUP]8[/SUP], Mazza L[SUP]3[/SUP], Santos MF[SUP]1[/SUP], Salvador NZ[SUP]1[/SUP], Gibson CM[SUP]9[/SUP], Granger CB[SUP]2[/SUP], Alexander JH[SUP]2[/SUP], de Souza OF[SUP]1,[/SUP][SUP]4[/SUP].
Author information
Abstract
Background:
Angiotensin-converting enzyme-2 (ACE2) may increase due to upregulation in patients using angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB). Because renin-angiotensin system blockers increase levels of ACE2, a protein that facilitates coronavirus entry into cells, there is concern that these drugs could increase the risk of developing a severe and fatal form of COVID-19. The impact of discontinuing ACEI and ARBs in patients with COVID-19 remains uncertain.DESIGNBRACE CORONA is a pragmatic, multicenter, randomized, phase IV, clinical trial that aims to enroll around 500 participants at 32 sites in Brazil. Participants will be identified from an ongoing national registry of suspected and confirmed cases of COVID-19. Eligible patients using renin-angiotensin system blockers (ACEI/ARBs) with a confirmed diagnosis of COVID-19 will be randomized to a strategy of continued ACEI/ARB treatment versus temporary discontinuation for 30 days. The primary outcome is the median days alive and out of the hospital at 30 days. Secondary outcomes include progression of COVID-19 disease, all-cause mortality, death from vascular causes, myocardial infarction, stroke, transient ischemic attack, new or worsening heart failure, myocarditis, pericarditis, arrhythmias, thromboembolic events, hypertensive crisis, respiratory failure, hemodynamic decompensation, sepsis, renal failure, troponin, B-type natriuretic peptide, N-terminal-pro hormone and D-dimer levels.
Summary:
BRACE CORONA will evaluate whether the strategy of continued ACEI/ARB therapy compared with temporary discontinuation of these drugs impacts clinical outcomes among patients with COVID-19.
? 2020 Elsevier Inc. All rights reserved.
PMID:32405071PMCID:PMC7219415DOI:10.1016/j.ahj.2020.05.002